(NASDAQ: PULM) Pulmatrix's forecast annual revenue growth rate of 238,066.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,228.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 1,339.67%.
Pulmatrix's revenue in 2025 is $3,000.On average, 3 Wall Street analysts forecast PULM's revenue for 2025 to be $26,095,576, with the lowest PULM revenue forecast at $25,072,937, and the highest PULM revenue forecast at $26,862,556.
In 2026, PULM is forecast to generate $61,292,647 in revenue, with the lowest revenue forecast at $58,889,443 and the highest revenue forecast at $63,096,876.